Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma PIK3CA Mutation Testing in Advanced Breast Cancer Patients for Personalized Medicine: A Value Proposition.

The journal of applied laboratory medicine - 1 Sept 2020

Ferreira-Gonzalez Andrea

Abstract excerpt

BACKGROUND: Even though endocrine therapy is often initially successful in treating advanced breast cancer, most patients inevitably face disease progression. In advanced hormone receptor-positive (HR+) breast cancer, activation of the PI3K downstream pathway is a critical feature of the mechanism of endocrine resistance. A significant recent advance in treating HR+ advanced breast cancer has been the recent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Precision Medicine

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 32901282
DOI: 10.1093/jalm/jfaa117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma PIK3CA Mutation Testing in Advanced Breast Cancer Patients for Personalized Medicine: A Value Proposition.PMID 32901282Read ↗

Circulating Tumor DNA in Cancer Management: A Value Proposition.Semantic proximity Read ↗

PIK3CA mutation detection by circulating tumor cell sequencing guides the effective PI3K inhibitor treatment of a patient with hormone receptor-positive breast cancer transformed into triple-negative breast cancer: A case report.Semantic proximity Read ↗

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.Semantic proximity Read ↗

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.Semantic proximity Read ↗

Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysis.Semantic proximity Read ↗

Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative studySemantic proximity Read ↗

Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.Semantic proximity Read ↗

Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.Semantic proximity Read ↗

The Diagnostic Accuracy of PIK3CA Mutations by circulating tumor DNA (ctDNA) in Breast Cancer: An Individual Patient Data Meta-analysisSemantic proximity Read ↗

Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.Semantic proximity Read ↗

Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer.Semantic proximity Read ↗

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.